TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04696705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo expanded allogeneic γδT cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
Study: NCT03784950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rating tool
Description: eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rating tool
Description: eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
Study: NCT04534842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1618
Description: 15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1934
Description: 15-day dose-ramp regimen (4 dose levels) of orally administered SYNB1934
Study: NCT01613339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training using Body awareness therapy
Description: Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
Study: NCT03822728

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D-DESS MRI (3 dimensional double echo steady state MRI)
Description: 3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
Study: NCT02915744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT05137964

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D
Description: Serum Biochemical routine lab workup and gynaecological ultra sound AFC
Study: NCT00988039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluvia + raltegravir
Description: Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily
Study: NCT04628780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209960
Description: PD-1 targeted IL-15 mutein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209960
Description: PD-1 targeted IL-15 mutein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209960
Description: PD-1 targeted IL-15 mutein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07209960
Description: PD-1 targeted IL-15 mutein
Study: NCT00988039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluvia monotherapy
Description: Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only
Study: NCT02401165

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: blood test
Study: NCT03254199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX-787-ODT (orally disintegrating tablet)
Description: FLX-787-ODT taken three times daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ODT
Description: Placebo ODT taken three times daily for 28 days
Study: NCT00778115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide HCl 2 mg and simethicone 125 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide HCl 2 mg and simethicone 125 mg tablets
Study: NCT03884790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surgical repair of long bone defects
Description: Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects.
Study: NCT01492205

Intervention type: DRUG
Intervention: insulin human
Description: All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
Study: NCT02792400

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2403021
Description: Glucagon receptor antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2403021
Description: Glucagon receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2403021
Description: Glucagon receptor antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2403021
Description: Glucagon receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2403021 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2403021 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2403021 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2403021 placebo

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardised liquid meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: DPP-4-inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: DPP-4-inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin placebo
Study: NCT00421681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong! Exercise Program
Description: Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong! Exercise Program
Description: Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
Study: NCT02392806

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble CPAP- BabiPlus, Respiralogics
Description: Infant will be randomized to BabiPlus Bubbler at time of extubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble CPAP- B&B Bubbler, B&B Medical devices
Description: Infant will be randomized to B\&B Bubbler at time of extubation
Study: NCT02792400

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: SGLT2-inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: SGLT2-inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin placebo
Study: NCT02768935

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sample
Description: blodd sample at 12 months
Study: NCT00503269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Hemorrhoidectomy under local anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: General anaesthetic haemorrhoidectomy
Study: NCT05598281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral tablet
Study: NCT04378270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PopSole™ Offloading Device
Description: Specifically, the PopSole™ Offloading Device allows the provider to pop bubbles in the device (like popping paper or plastic bubble sheeting), thereby offloading the surgical area or area of pain. This customizable approach to offloading may increase compliance as it can easily fit in a normal walking shoe and is personalized for each patient. It can also be attached to a slide for use in the shower. Currently no post-operative devices for offloading the foot can be used in the shower.
Study: NCT03035799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Description: Paleolithic diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Healthful Diet
Description: General Healthful Diet
Study: NCT02915744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Study: NCT01461434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Reveal XT implantable loop recorder
Description: subcutaneous implantation
Study: NCT00965393

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Systemic infusion of placebo (saline)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bradykinin receptor antagonist (HOE-140)
Description: Systemic infusion of bradykinin receptor antagonist (HOE-140)
Study: NCT00618800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care
Description: Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written Materials
Description: Participants receive written information about falls prevention.
Study: NCT00557986

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary surgery
Description: Primary breast surgery before systemic therapy
Study: NCT04187937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic image-guided resection
Description: Stereotactic image-guided resection with an ultrasound-based image-guidance system.
Study: NCT05592704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usage of a wearable heart rate monitor and a smartphone with the application for home-based exercises
Description: Physical activity self-monitoring using a wearable heart rate monitor and a smartphone with specially designed application
Study: NCT00902486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB028050
Description: 4 mg capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB028050
Description: 7 mg capsules QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB028050
Description: 10 mg capsule QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching INCB028050 QD
Study: NCT02058459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holaira™ Lung Denervation System with energy delivery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Holaira™ Lung Denervation System without energy delivery
Study: NCT01700907

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
Study: NCT01097759

Intervention type: PROCEDURE
Intervention: Surgery
Description: Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler

Intervention type: PROCEDURE
Intervention: Surgery
Description: Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
Study: NCT03612830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy endoscopy cooperated surgery
Description: LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dan Vinchi robot endoscopy cooperated surgery
Description: RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
Study: NCT01708252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT00213629

Intervention type: OTHER
Group type: OTHER
Intervention: transcriptome analysis
Description: transcriptome analysis from muscle biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: T cell repertoire analysis
Description: blood T cell repertoire analysis
Study: NCT01055184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2009 H1N1 Virus Vaccine
Description: Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
Study: NCT00860054

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Different amount of phytosterols are added into diets
Description: Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Different amount of phytosterols are added into diets
Description: Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Different amount of phytosterols are added into diets
Description: Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
Study: NCT01419405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: hard capsule, 150 mg, 2 times, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: hard capsule, 150 mg, 2 times, 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
Study: NCT02664662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tailored education
Description: Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
Study: NCT00517881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
Description: Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
Study: NCT00800267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005%
Description: placebo in the morning and latanoprost .005% in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed combination latanoprost-timolol
Description: one drop in the morning and placebo in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5%
Description: one drop in the morning and evening
Study: NCT01950455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAV5001
Description: A single intravenous dose of 8.0 ± 1.0 mCi
Study: NCT04389229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600mg/m2/day for 3 days ( on day -5, -4, -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600mg/m2/day for 3 days ( on day -5, -4, -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: 30mg/m2/day for 3 days ( on day -5, -4, -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: 30mg/m2/day for 3 days ( on day -5, -4, -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 (Proleukin)
Description: Subcutaneous injections at a fixed dose of 18 million units once a day following TIL infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 (Proleukin)
Description: Subcutaneous injections at a fixed dose of 18 million units once a day following TIL infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)
Description: Single dose at 5 x 10\^9 - 5 x 10\^10

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)
Description: Single dose at 2 x10\^9 (+/- 20%) (engineered TIL)
Study: NCT00449904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally
Study: NCT04271228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro
Description: Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use